Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.
Kota FukumotoTran B NguyenShigeru ChibaMamiko Sakata-YanagimotoPublished in: Cancer science (2017)
Angioimmunoblastic T-cell lymphoma (AITL) is an age-related malignant lymphoma, characterized by immune system-dysregulated symptoms. Recent sequencing studies have clarified the recurrent mutations in ras homology family member A (RHOA) and in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2), DNA methyl transferase 3 alpha (DNMT3A) and isocitrate dehydrogenase 2, mitochondrial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL. In this review, we focus on how this genetic information has changed the understanding of the developmental process of AITL and will in future lead to individualized therapies for AITL patients.
Keyphrases
- genome wide
- dna methylation
- end stage renal disease
- signaling pathway
- wild type
- rheumatoid arthritis
- chronic kidney disease
- ejection fraction
- newly diagnosed
- gene expression
- oxidative stress
- peritoneal dialysis
- copy number
- prognostic factors
- epithelial mesenchymal transition
- single cell
- low grade
- healthcare
- circulating tumor
- patient reported outcomes
- transcription factor
- cell free
- physical activity
- single molecule
- cell proliferation
- induced apoptosis